A trial to learn how safe durvalumab with chemotherapy is and how well it works in adults with muscle-invasive bladder cancer
EU CTIS ID: 2024-519246-75-01
What this study is testing
To assess the safety of neoadjuvant durvalumab combined with ddMVAC prior to RC.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient resectable muscle-invasive bladder cancer with clinical stage T2-T4aN0/1M0 or T1N1M0 with transitional cell histology
- Patients must be planning to undergo a radical cystectomy at the time of randomization;
- An ECOG performance status of 0 or 1 at enrolment.
- Must have a life expectancy of at least 12 weeks at first dose of study medication.
- Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of MIBC
You likely can't join if
- Evidence of lymph node involvement (N2-N3) or metastatic disease at the time of screening.
- Requires immunosuppression medication for a concomitant condition.
- Contra-indication to any of the study drugs.
- Active or prior documented autoimmune or inflammatory disorders (exceptions apply)
The study team makes the final eligibility decision.
Where it's taking place
- Italy
- Spain
- France
- Netherlands
- Australia
- Brazil
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Italy; Spain; France; Netherlands; Australia; Brazil and 1 more location. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from EU CTIS. The study team decides eligibility, and your own doctor gives medical advice.